TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25694056
Drug: Candesartan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (16 mg to 32 mg per day) in addition to routine standard of care
Study: 22074866
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading (IML) implants
Study: 22074866
Drug: Conventional loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional loading implants
Study: 19444561
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration therapy (1000 ml of oral rehydration solution)
Study: 19444561
Drug: Intravenous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous therapy (1000 ml of intravenous electrolyte solution)
Study: 15198290
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (Genotropin, 1 mg/m2/day)
Study: 11438316
Drug: Testosterone lozenge
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone lozenge (1 mg)
Study: 11438316
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (1 mg)
Study: 9692520
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg orally every 12 h for 10 days
Study: 9593146
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg orally every 24 h for 10 days
Study: 9593146
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clarithromycin and loratadine
Study: 9593146
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three regimens (clarithromycin, loratadine, combination)
Study: 7874080
Drug: Thymomodulin 10
Normalized name: thymomodulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymomodulin 10 mg three times per week for 2 months
Study: 2896957
Drug: Treatment combined
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment combined with fortnightly chemoprophylaxis with 'Maloprim' (pyrimethamine/dapsone)
Study: 2896957
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of presumptive episodes of clinical malaria with chloroquine
Study: 25572706
Drug: Baclofen 50
Normalized name: baclofen 50 mcg/mL INTRATHEC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 50 mg/day
Study: 16679630
Drug: Intravenous L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine 20 mg/kg after every dialysis session for 8 weeks
Study: 15090626
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 g of high oleic acid sunflower oil)
Study: 15090626
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of cis‐9,trans‐11 (c9t11) CLA
Study: 15090626
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of cis‐9,trans‐11 (c9t11) CLA
Study: 15090626
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of trans‐10,cis‐12 (t10c12) CLA
Study: 15090626
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of trans‐10,cis‐12 (t10c12) CLA
Study: 10856731
Drug: Metoprolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (mean final dosage 135 mg/day)
Study: 9355892
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (200 mg TID)
Study: 3890036
Drug: Mepivacaine hydrochloride
Normalized name: Mepivacaine Hydrochloride
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mepivacaine hydrochloride (1% solution)
Study: 20306937
Drug: Involvement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involvement of hospital chaplains in spiritual care during treatment.
Study: 28973430
Drug: Antecedent hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antecedent hypoglycemia (3 periods of 45 minutes at 2.8 mmol/L)
Study: 28973430
Drug: Control (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (3 periods of 45 minutes at 6 mmol/L)
Study: 25932792
Drug: Combo therapy
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combo therapy (ERN + P-OM3)
Study: 16861099
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg QD
Study: 12963170
Drug: Oral-conjugated oestrogen
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-conjugated oestrogen 0.625 mg daily (n=13)
Study: 12963170
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen patches 50 microg daily (n=10)
Study: 10720589
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg for 1 month)
Study: 3299567
Drug: Ambroxol retard
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol retard (75 mg)
Study: 29065710
Drug: Yoghurt drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoghurt drink containing Lactobacillus strains (125 g, twice daily for 4 weeks)
Study: 29065710
Drug: Placebo (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (125 g chemically acidified milk, twice daily for 4 weeks)
Study: 23607963
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin E once daily
Study: 23607963
Drug: Emollient once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emollient once daily
Study: 11041396
Drug: rBPI21 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBPI21 (2 mg/kg over 30 min followed by 2 mg/kg over 24 h)
Study: 11041396
Drug: Placebo (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.2 mg/mL human albumin solution)
Study: 8769511
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gluconate (CHX) oral rinse
Study: 27090649
Drug: Pressure-Controlled Ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure-Controlled Ventilation (PCV) targeting large V T (15 mL × kg(‐1))
Study: 19717399
Drug: TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitors + methotrexate (MTX)
Study: 15886247
Drug: Metformin 2550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2550 mg/d
Study: 8874243
Drug: Smoked cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cocaine base (38.5 +/- 2.3 mg)
Study: 8874243
Drug: i.v. cocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. cocaine HCl (30.0 +/- 2.0 mg)
Study: 8874243
Drug: Smoked placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked placebo (2.3 +/- 0.9 mg cocaine base)
Study: 8874243
Drug: i.v. saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. saline solution placebo
Study: 1509861
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ciprofloxacin b.i.d. for 5 days
Study: 6714054
Drug: Cimetidine and
Normalized name: Cimetidine and sodium alginate only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine and antacid suspension
Study: 30919249
Drug: Perindopril/Amlodipine SPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril/Amlodipine SPC (3.5/2.5 mg to 14/10 mg)
Study: 30919249
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg to 300/25 mg)
Study: 19937046
Drug: SCH486757 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH486757 100 mg
Study: 15825069
Drug: Ornidazole 1
Normalized name: ornidazole 167 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole 1 g/day
Study: 12442930
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% 30 mL (+epinephrine 5 microg mL(‐1))
Study: 12442930
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% 15 mL (+epinephrine 5 microg mL(‐1))
Study: 1850870
Drug: Breast-preserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-preserving therapy with interdisciplinary communication among therapists (surgeon, radiotherapist, oncologist) and pathologist.
Study: 1850870
Drug: Breast-preserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-preserving therapy under unfavorable prerequisites for cosmetically satisfactory results.
Study: 6345013
Drug: Mefloquine 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 1000 mg
Study: 6345013
Drug: Mefloquine 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 750 mg
Study: 6345013
Drug: Mefloquine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 500 mg
Study: 30628088
Drug: Adjunctive azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive azithromycin (500 mg for 3 days)
Study: 30628088
Drug: Adjunctive amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive amoxicillin plus metronidazole (500 mg AMX plus 400 mg MTZ three times per day for 7 days)
Study: 22969203
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (PAM): pantoprazole 20 mg bid, amoxicillin 1 g bid, moxifloxacin 400 mg bid for 10 days
Study: 22969203
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (PAMB): pantoprazole 20 mg bid, amoxicillin 1 g bid, moxifloxacin 400 mg bid, bismuth subcitrate 240 mg bid for 10 days
Study: 18001671
Drug: Cognitive-behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural treatment for smoking cessation without nicotine replacement
Study: 12577415
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) plus Xiaoliu Pingyi Mixture (XLPYM)
Study: 7984290
Drug: Zatosetron (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zatosetron (13 mg or 0.19 mg/kg)
Study: 2644533
Drug: Adjuvant combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil, leucovorin) administered on days 1 and 8, starting within 36 hours after mastectomy
Study: 19938102
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) at a standard dose of 2g per kg body weight
Study: 15170013
Drug: COL-1492 vaginal
Normalized name: Col-118
DrugBank: Col-118 (DB05778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COL-1492 vaginal gel containing 52.5 mg nonoxynol-9
Study: 10052024
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 ml saline intravenous)
Study: 3142396
Drug: Methyldopa (MD)
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa (MD) 500 mg/bid, optimal dosage up to 1500 mg/bid
Study: 3142396
Drug: Labetalol (LAB)
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Labetalol (LAB) 400 mg/bid, optimal dosage up to 1200 mg/bid
Study: 3142396
Drug: Acebutolol (ACE)
DrugBank: Acebutolol (DB01193)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acebutolol (ACE) 400 mg/bid, optimal dosage up to 1200 mg/bid
Study: 30088008
Drug: 36-month family-based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36-month family-based, community-centered program (n=304 pairs) consisting of 12 weekly skills-building sessions, followed by monthly coaching calls for 9 months, and a 24-month sustainability phase.
Study: 27623957
Drug: mesalazine 1200
Normalized name: mesalamine 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine 1200 mg plus a probiotic blend (Lactobacillus salivarius, Lactobacillus acidophilus, Bifidobacterium bifidus strain BGN4)
Study: 27623957
Drug: mesalazine 1200
Normalized name: mesalamine 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine 1200 mg
Study: 10435394
Drug: Risperidone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1 mg single oral dose)
Study: 7004559
Drug: Intravenous fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluorouracil, cyclophosphamide, methotrexate, and vincristine given over five days followed by intravenous fluorouracil and mitomycin given over three or five days at six-week intervals thereafter
Study: 26488269
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard CDC information factsheet on HPV vaccine)
Study: 22526891
Drug: Intraseptal anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraseptal anesthesia (ISA) with 4% articaine + 1:100,000 epinephrine (16 mg + 4 μg, 24 mg + 6 μg, 32 mg + 8 μg)
Study: 22526891
Drug: Periodontal ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal ligament anesthesia (PLA) with 4% articaine + 1:100,000 epinephrine (16 mg + 4 μg, 24 mg + 6 μg, 32 mg + 8 μg)
Study: 21546066
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (specifics not provided)
Study: 21546066
Drug: CA-125 PFS
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA-125 PFS status at 4 months (PFS4) in combination treatment
Study: 21546066
Drug: CA-125 response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CA-125 response in combination treatment
Study: 21546066
Drug: CA-125 PFS4
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA-125 PFS4 in combination treatment
Study: 17990464
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard therapy without QYD and GS)
Study: 9803988
Drug: Zabicipril (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zabicipril (0.5 mg)
Study: 9803988
Drug: Zabicipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zabicipril (2.5 mg)
Study: 389121
Drug: Pharmacologically inactive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologically inactive dose (1 mg)
Study: 25087311
Drug: Pentavac administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavac administered second (Group A)
Study: 25087311
Drug: Pentavac administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavac administered first (Group B)
Study: 15010066
Drug: Glufosfamide 5000
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glufosfamide 5000 mg/m² by 1-hour intravenous infusion every 3 weeks
Study: 11758323
Drug: Infiltration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration of 0.5% bupivacaine into the surgical wound before surgery combined with general anesthesia (Group L)
Study: 30908574
Drug: Paracetamol responders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol responders
Study: 30908574
Drug: Paracetamol nonresponders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol nonresponders
Study: 29550881
Drug: Nabilone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (0.5 mg/2 weeks followed by 1.0 mg/6 weeks)
Study: 23302446
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 0.625 mg/day for 4 weeks with antipsychotic treatment
Study: 23302446
Drug: Placebo booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo booster with antipsychotics
Study: 15806975
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection (SFI) plus stanozol and cyclosporin A
Study: 7574195
Drug: Azithromycin prophylaxis
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin prophylaxis (250 mg/d) for cohort 1, administered as 500 mg on day 14 before challenge, followed by 250 mg/d from day 13 before challenge through day 7 after challenge.
Study: 7574195
Drug: Azithromycin prophylaxis
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin prophylaxis (250 mg/d) for cohort 2, continued for 28 days after the challenge.
Study: 7574195
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) for both cohorts.
Study: 2037705
Drug: Pinacidil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (0.1 mg/kg)
Study: 2037705
Drug: Pinacidil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (0.1 mg/kg) with propranolol pretreatment
Study: 7308332
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg bromhexine (4 mg in two patients)
Study: 31124581
Drug: Dexamethasone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (6 mg/m²/day)
Study: 31124581
Drug: Prednisolone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (60 mg/m²/day)
Study: 29032379
Drug: Oral bicarbonate
Normalized name: sodium bicarbonate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bicarbonate
Study: 19725342
Drug: Sugammadex administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex administered at a dosage of 2 mg x kg(‐1)
Study: 18027087
Drug: Post-operative radiation
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative radiation therapy (largely eliminated)
Study: 18027087
Drug: Comparative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative treatment regimens (randomized trials)
Study: 15130189
Drug: Balanced and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced and complementary processing of text/adjunct information
Study: 8091361
Drug: SR 25776
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 25776 500 mg
Study: 30460402
Drug: Tonsillectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonsillectomy plus platelet-rich plasma (PRP) therapy (TPRP group)
Study: 28870263
Drug: 3000 IU
Normalized name: Cholecalciferol 3000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 IU vitamin D3 taken daily from randomization in pregnancy until trial discharge at 12 months postpartum
Study: 16569797
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium delayed-release (DR)
Study: 16569797
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium extended-release (ER)
Study: 8721265
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (160 mg/d)
Study: 1551152
Drug: Rectal ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal ibuprofen (40 mg.kg‐1.day‐1 in divided doses)
Study: 31233117
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAAs) in primary care
Study: 29688793
Drug: High-dose BNR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BNR (BNR-H, 1010 CFU/day)
Study: 29688793
Drug: Low-dose BNR
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose BNR (BNR-L, 109 CFU/day)
Study: 26456200
Drug: Intra-arterial therapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial therapy (IA therapy)
Study: 24866496
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose resveratrol (300mg/day)
Study: 24866496
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose resveratrol (1000mg/day)
Study: 15813664
Drug: Albuterol HFA
Normalized name: Albuterol Sulfate 0.09 MG/1 ACTUATION Inhalation Aerosol Powder [ALBUTEROL HFA]
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol HFA (Ventoline) 2 x 100microg
Study: 1646240
Drug: Fosinopril sodium
Normalized name: Fosinopril Sodium
DrugBank: Fosinopril (DB00492)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosinopril sodium (SQ 28,555) 10 to 640 mg once daily for 3 days
Study: 1646240
Drug: Fosinopril sodium
Normalized name: Fosinopril Sodium
DrugBank: Fosinopril (DB00492)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosinopril sodium (SQ 28,555) 80 mg bid and 160 mg bid for 2 weeks
Study: 6274372
Drug: Glycopyrrolate combined
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate combined with antacid
Study: 6274372
Drug: Atropine combined
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine combined with antacid
Study: 6274372
Drug: Saline combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline combined with antacid
Study: 10393682
Drug: Ganciclovir (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (no calcium blockers)
Study: 10393682
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no calcium blockers)
Study: 10393682
Drug: Ganciclovir (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (with calcium blockers)
Study: 10393682
Drug: Placebo (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with calcium blockers)